BI-1607
Product Specifications
Target
Others
Related Pathways
Others
Bioactivity
BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. It acts as an antagonist, capable of blocking the inhibitory effects of FcγRIIB on immune effector cells. When used in combination with Trastuzumab, BI-1607 can significantly suppress HER2-positive solid tumors, including advanced gastric cancer (GC) .
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog